Bristol Myers Camzyos Shows Strong Results in HCM Trial
PRINCETON, N.J., USA, March 29, 2026 Bristol Myers Squibb has announced positive Phase 3 results from the SCOUT-HCM trial...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
PRINCETON, N.J., USA, March 29, 2026 Bristol Myers Squibb has announced positive Phase 3 results from the SCOUT-HCM trial...
February 24, 2026 – Cincinnati, Ohio & Tacoma, Washington, USA Cincinnati Children’s Hospital Medical Center has announced a strategic...
Abbott Park, Illinois, December 18, 2025 — Abbott has secured U.S. Food and Drug Administration (FDA) clearance and CE...
